Twist Bioscience Corporation (TWST) Earnings
Twist Bioscience Corporation is expected to report next earnings on August 3, 2026 (in NaN days), with a consensus EPS estimate of $-0.48. TWST has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise -1.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $-0.49 | $-0.62 | -26.5% | $111M | +2.9% |
| Feb 2, 2026 | $-0.48 | $-0.50 | -4.2% | $104M | -3.7% |
| Nov 14, 2025 | $-0.50 | $-0.45 | +10.0% | $99M | +1.7% |
| Feb 3, 2025 | $-0.62 | $-0.53 | +14.5% | $89M | +2.0% |
| Nov 18, 2024 | $-0.71 | $-0.59 | +17.4% | $85M | +2.4% |
| Aug 2, 2024 | $-0.79 | $-0.86 | -8.9% | $81M | -0.9% |
| May 2, 2024 | $-0.84 | $-0.79 | +6.0% | $75M | -2.7% |
| Feb 2, 2024 | $-0.80 | $-0.75 | +6.3% | $71M | +5.8% |
| Nov 17, 2023 | $-0.94 | $-0.81 | +13.8% | $67M | +5.7% |
| Aug 4, 2023 | $-1.14 | $-1.01 | +11.4% | $64M | +5.3% |
| May 5, 2023 | $-1.09 | $-1.06 | +2.8% | $60M | +6.2% |
| Feb 3, 2023 | $-1.09 | $-0.74 | +32.1% | $54M | -0.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · May 4, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Twist posted 13th quarter of sequential revenue growth and outperformed broader lifetime tools market. - Twist Core Technology Advantage is semiconductor-based DNA synthesis platform providing cost, scale, speed advantage. - DNA synthesis and protein solutions grew 28% powered by AI-enabled drug discovery, with work with AWS on Amazon BioDiscovery as validation. - NGS tools business is durable and growing, strong in oncology diagnostics, with target enrichment and lab prep solutions. - Plan to accept more sequences and improve acceptance rates, anchored strategy around end applications with depth and breadth across biological continuum. - Deliberate investment in commercial organization and digital infrastructure to support growth.
Guidance
For fiscal 2026, expect total revenue of $442 million to $447 million, growth of approximately 17% to 19%. For Q3 of fiscal 2026, expect total revenue of $114 million to $115 million, growth of approximately 19% year-over-year at midpoint. Expect NGS to be driver of sequential growth in H2 and return to 20% growth by Q4. Expect reaching adjusted EBITDA breakeven for fourth quarter of fiscal 2026.
Segment performance
Total revenue grew to $110.7 million, up more than 19% year-over-year. DNA synthesis and protein solutions grew 28%, with revenue increasing to $53.3 million. NGS applications grew 12% year-over-year and 9% sequentially, with revenue reaching approximately $57.4 million. America's revenue increased to approximately $64.3 million, EMEA revenue rose to $37.3 million, APAC revenue increased to $9.1 million. Therapeutics revenue rose to $40.8 million, diagnostics revenue was $40 million, industry and applied revenue was $5.8 million, academic research and government revenue was $12.8 million, global supply partner revenue was $11.4 million. Gross margin expanded to 51.6% versus the prior year.
Analyst Q&A
Q: Discuss how AI-driven workflows performed in the quarter relative to internal expectations and contribution to updated fiscal guidance.
A: SPS grew 28% year-over-year, AI-driven discovery increased number of sequences and overall value of deals.
Q: How much of therapeutics 55% growth in second quarter was driven by AI-related programs?
A: AI has been source of strength, with many accounts driving growth now, not just a few.
Q: On academic and government end market, are things stabilizing or improving?
A: Academic end market suffering from funding pressures but Twist taking market share with premium discount.
Q: On gross margin, was down nominally sequentially. Any callout?
A: Deliberate investment in IGG and characterization for AI discovery projects and digital capabilities, confident in 52% guide for year.
Q: Follow up on gross margin improvement and automated workflows.
A: Front end is silicon chip, backend varies by product, adding automation on needed branches, and automating automation.
Q: You increased full-year revenue guidance. Any specific area driving increase?
A: Back half improvements, continued increases in DSPS revenue, opportunity to get new customers into DSPS side.
Q: Timeline for complex DNA offering products and additional opportunity.
A: Focused on customer experience, goal is one-stop shop, broad sequence acceptance, looking forward to scaling in coming quarters.
Q: On margin side, how to think about leverage beyond adjusted EBITDA breakeven in fourth quarter?
A: Laser focused on crossing adjusted EBITDA positives in Q4 while maximizing revenue growth, stewards of market, will discuss more at investor day.
Q: Color on genes for characterization this quarter and AI demand.
A: Growth in genes used internally to generate data, AI demand with customers shifting from bidding model to turning the crank.
Q: Pin in AI orders questioning, run rate for FY26 and revenue breakdown.
A: Predominantly AI discovery work driving outsized growth in therapeutics, hard to know exact number of discovery vs classic work.
Q: On diagnostics growth, incremental sequential growth through rest of year?
A: Seeing growth, confident in NGS part of business, portfolio of panels enables great growth, looking forward to return to growth.